- Home
- ACXP vs PYPD Comparison
ACXP vs PYPD Comparison
Compare ACXP & PYPD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACXP
- PYPD
- Stock Information
- Founded
- ACXP 2017
- PYPD 2008
- Country
- ACXP United States
- PYPD Israel
- Employees
- ACXP N/A
- PYPD N/A
- Industry
- ACXP Biotechnology: Pharmaceutical Preparations
- PYPD Medical/Dental Instruments
- Sector
- ACXP Health Care
- PYPD Health Care
- Exchange
- ACXP Nasdaq
- PYPD Nasdaq
- Market Cap
- ACXP 8.4M
- PYPD 36.0M
- IPO Year
- ACXP 2021
- PYPD 2020
- Fundamental
- Price
- ACXP $0.43
- PYPD $3.52
- Analyst Decision
- ACXP Strong Buy
- PYPD Strong Buy
- Analyst Count
- ACXP 2
- PYPD 5
- Target Price
- ACXP $10.00
- PYPD $11.40
- AVG Volume (30 Days)
- ACXP 18.7M
- PYPD 199.2K
- Earning Date
- ACXP 08-08-2025
- PYPD 08-13-2025
- Dividend Yield
- ACXP N/A
- PYPD N/A
- EPS Growth
- ACXP N/A
- PYPD N/A
- EPS
- ACXP N/A
- PYPD N/A
- Revenue
- ACXP N/A
- PYPD N/A
- Revenue This Year
- ACXP N/A
- PYPD N/A
- Revenue Next Year
- ACXP N/A
- PYPD N/A
- P/E Ratio
- ACXP N/A
- PYPD N/A
- Revenue Growth
- ACXP N/A
- PYPD N/A
- 52 Week Low
- ACXP $0.30
- PYPD $2.30
- 52 Week High
- ACXP $3.33
- PYPD $4.42
- Technical
- Relative Strength Index (RSI)
- ACXP 46.13
- PYPD 47.79
- Support Level
- ACXP $0.45
- PYPD $3.34
- Resistance Level
- ACXP $0.59
- PYPD $3.53
- Average True Range (ATR)
- ACXP 0.07
- PYPD 0.13
- MACD
- ACXP -0.01
- PYPD -0.05
- Stochastic Oscillator
- ACXP 10.73
- PYPD 6.82
About ACXP Acurx Pharmaceuticals Inc.
Acurx Pharmaceuticals Inc is a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization, Centers for Disease Control and Prevention and Food and Drug Administration. The company's approach is to develop antibiotic candidates with a Gram-positive selective spectrum. The Company's segment consists of the development of clinical and preclinical product candidates for the development of the Company's proprietary new therapies.
About PYPD PolyPid Ltd.
PolyPid Ltd is a clinical-stage biopharmaceutical company engaged in the research and development of products based on PLEX (Polymer-Lipid Encapsulation MatriX), the company's proprietary drug delivery technology. PLEX is capable of encapsulating many types of drugs to enable targeted, localized drug delivery into the body over extended periods of time with pre-determined release rates thus optimizing drug treatment regimens. BonyPid, PolyPid, Opzifend, Ssisurg, Elyfssi, Baczenssi, Opzifend and Bacyssio are trademarks of the company. Its product candidate include D-PLEX100 for prevention of SSI in soft tissue and OncoPLEX which can be a potential Intra-tumoral therapy.